口服普萘洛尔治疗婴幼儿增生期血管瘤35例临床分析

目的:探讨口服普萘洛尔治疗婴幼儿增生期血管瘤的临床疗效。方法:2009年10月—2011年2月,35例增生期血管瘤患儿在中国医科大学附属口腔医院完成普萘洛尔治疗,按1.0～1.5mg/kg,每天1次口服用药,连续服用,随访1～10个月。收集每例患儿的相关资料,包括临床特征、疗效和不良反应。采用半球测量法和数码照片记录患儿血管瘤大小,按家长反馈信息和4级评分法对疗效进行评价。结果:口服普萘洛尔治疗后,大部分血管瘤体积明显减小,颜色变淡,质地变软,家长满意度好,不良反应轻微。疗效评定为Ⅳ级(优)者6例,Ⅲ级(好)16例,Ⅱ级(中)10例,I级(差)3例。结论:口服普萘洛尔作为一种新型的治疗方式,用药安全,疗效明显,对体积较大的血管瘤疗效显著。

Oral propranolol treatment for infants with proliferating hemangiomas: clinical analysis of 35 cases

PURPOSE: Oral propranolol is a very recent therapeutic option for infantile hemangiomas.The purpose of this study was to investigate the clinical efficacy of propranolol in treating proliferating hemangiomas.METHODS: Between October 2009 and February 2010,oral propranolol was applied to 35 infants with hemangiomas at a dose of 1.0～1.5mg/kg/day in School of Stomatology,China Medical University.There were 12 males and 23 females aged 2 to 12 months with a mean age of 5.6 months.The primary tumor size was 2.2cm×1.5cm to 15.0 cm×6.0cm.All the infants were followed up for 1 months to 10 months.The information about clinical characters,treatments and adverse reactions were collected.Hemisphere measurements and digital photos were used to record the size of hemangiomas.4 score method and feedback from parents have been used to evaluate the clinical curative effects.RESULTS: Most tumors decreased in texture,color and size,with less adverse reactions after taking medication.The overall response was scale Ⅳ(excellent) in 6 patients,scale Ⅲ(good) in 16 patients,scale II(moderate)in 10 patients,and scale I(poor) in 3 patients.CONCLUSIONS: Propranolol can be used as a new therapeutic modality for infantile hemangiomas during the proliferating phase which is safe and effective,has clinical value,especially for larger hemangiomas.